Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cadence Pharmaceuticals, a biopharmaceutical company, has appointed Todd Rich to its board of directors and Malcolm Lloyd-Smith as senior vice president of regulatory affairs and quality assurance.
Subscribe to our email newsletter
Mr Lloyd-Smith assumes the role previously held by Malvina Laudicina, who resigned from the company for medical reasons.
Mr Lloyd-Smith joins Cadence from Elan Pharmaceuticals, where he was most recently vice president and head of global regulatory affairs. Mr Lloyd-Smith received his MS in pharmacological biochemistry from Hatfield Polytechnic and his BS in pharmacology from the University of Leeds.
Dr Rich is currently vice president of development regulatory, medical information, drug safety, quality and compliance at Genentech. Dr Rich holds an MD from Wayne State University and an MBA from the Stanford University Graduate School of Business.
James Breitmeyer, executive vice president and chief medical officer of Cadence, said: “Malcolm will play a key role in helping us achieve our regulatory objectives for our two Phase III product candidates, Acetavance for the treatment of acute pain and fever, and Omigard for the prevention of catheter-related infections.”